Biomedical Systems Releases Telemetry Device for Long-Term ECG Monitoring

Biomedical Systems, a digital imaging, cardiac diagnostic services and clinical equipment provider, has revealed the TruVue Wireless Ambulatory ECG Monitoring System. The telemetry device has been developed for diagnosing and managing atrial fibrillation and other cardiac arrhythmia.

The TruVue is a diagnostic recording device, which can monitor the heartbeat for a period of 30 days, analyze advanced arrhythmia and transmit the data so that cardiologists and electrophysiologists can access the transmitted ECG. The sensor device features automatic wireless data transmission and an arrhythmia analysis algorithm. It provides the advantages of both cardiac and Holter event monitor in a single device.

The TruVue ECG monitoring device was developed by Biomedical Systems in response to the physicians’ demand for an ECG monitoring device capable of monitoring the patient for extended periods and diagnosing the symptoms of cardiac arrhythmia along with aiding in the treatment of patients.

The patient attaches the TruVue sensor to the chest with three electrodes. The sensor digitizes the two-channel electrocardiogram continuously and transmits the data to a handheld unit using Bluetooth technology. This enables the patients to carry the device wherever they go. The handheld device transmits the digitized ECG to a secure server where computer algorithms look for changes in rate, rhythm, morphology and other markers, round the clock. The analysis algorithm issues an alert for atrial fibrillation, supraventricular tachycardia, ventricular fibrillation, tachycardia, idioventricular rhythms, ventricular tachycardia, bradycardia and asystolic heartbeat. The findings and reports are validated by certified cardiac technicians who alert the physicians if required. Physicians can access the data and trend reports online including rhythm abnormalities and 24-hour heart rates.

The TruVueWireless Ambulatory ECG Monitoring System is being employed by medical device and pharmaceutical companies to assess the cardiovascular efficacy and safety of new devices and drugs.